Yet Another Value Podcast

The market has decided YouGov ($YOU.L) is an AI loser and cut it ~50% in a year. Jonathan Cohen of Zipperline Capital thinks it's an AI winner trading at 6-7x EBITDA, with a 20-year proprietary dataset AI makes more valuable, not less. We spend the first half on the UK as an "emerging market" (corporate governance discounts, why buybacks are finally happening, and why you can never compare UK and US multiples), then go deep on YouGov: the panel, the moat, synthetic data, and why the company is cancelling its dividend to buy back stock.This episode is sponsored by my upcoming AI webinar with AlphaSense.The AI landscape has never been more crowded — or more confusing. Everyone's telling you to adopt AI, but almost nobody's asking the harder question: which tools actually give you an edge?I'm sitting down with Dave Wang of Wall Street Prompt and Ben Collins of AlphaSense to break down the modern AI stack for investors — from horizontal platforms like OpenAI and Claude to agentic workflows and finance-specific intelligence tools — and where each one actually fits in a real research process. If you're trying to build an AI-enabled workflow that sharpens your judgment rather than replacing it, you won't want to miss this.Join us on June 25th - register now: https://www.alpha-sense.com/resources/webinars/choosing-your-ai-stack-a-framework-for-institutional-investors/?utm_source=pt_YAVP&utm_medium=sponsored&utm_campaign=SWB_DG_06-25-26_IMP-GENAI_CORPFS_YAVP-AI-SolutionsChapters:00:00 Why YouGov could be the AI winner the market is misreading02:56 Why Jonathan Cohen runs a UK and Europe small/mid-cap book08:01 Why you can never compare UK and US multiples13:08 What UK analyst coverage actually tells you17:37 The shift toward UK buybacks and capital allocation22:00 The "buybacks kill liquidity" myth25:11 What YouGov really is: a proprietary data business31:19 Inside the panel: why people answer, and why retention is the moat36:52 Why the market thinks YouGov is an AI loser38:19 The bull case: why AI makes YouGov more valuable40:55 Synthetic data, and why it breaks46:28 Trust as a moat in a world of AI slop52:27 Pushback: Chegg, Wix, and the real AI losers56:51 Content businesses vs distribution businesses01:00:14 Music, media, and what compounds through disruption01:05:38 ClosingLinks:Yet Another Value Blog - https://www.yetanothervalueblog.comSee our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimerProduction and editing by The Podcast Consultant - https://thepodcastconsultant.com/

Alex Roepers of Atlantic Investment Management lays out two deeply cheap special situations: Dauch (DCH) and Nomad Foods (NOMD). In both, management is sending "dark arts" signals (an aggressive CEO payout struck well above the current price, heavy insider buying) that point to an inflection the market hasn't paid for yet. We dig into the $300M merger synergies at Dauch, the auto-cycle and leverage risk, the governance red flags, the private-label threat to Nomad's frozen-food brands, and whether the European discount on both is real or just doldrums.This episode is sponsored by AlphaSense. Join Andrew, Dave Wang of Wall Street Prompts, and Ben Collins of AlphaSense for a webinar breaking down the modern AI stack for investors: where horizontal platforms, agentic workflows, and finance-specific tools each actually fit in a real research process. Recording June 16, live June 25. Register here: https://www.alpha-sense.com/resources/webinars/choosing-your-ai-stack-a-framework-for-institutional-investors/?utm_source=pt_YAVP&utm_medium=sponsored&utm_campaign=SWB_DG_06-25-26_IMP-GENAI_CORPFS_YAVP-AI-SolutionsDisclosure: long DCH and NOMDChapters:0:00 Two cheap special situations and the "dark arts" setup1:10 Sponsor: AlphaSense and the AI-stack-for-investors webinar2:29 Alex Roepers, Atlantic Investment Management3:04 Dauch ($DCH): the GKN, Melrose and Dowlais backstory7:05 Why Atlantic made $DCH a core position at ~$69:03 The governance knock: a company named after a sub-1% CEO13:42 Dark arts: the PSU grant that only pays above $1215:11 Underwriting the $300M merger synergies18:13 Leverage, capital allocation and the path to buybacks24:42 The auto cycle and why 5x free cash flow caps the downside29:12 Nomad Foods ($NOMD): the frozen-food bull case33:14 Nomad by the numbers: 5.5x earnings, 7% yield35:39 The bear case: private label, Aldi and a new CEO39:21 Would Martin Franklin ever sell?41:22 Dividend or buyback at these levels?43:00 Is Franklin distracted by APi Group?45:27 The kitchen-sink reset and a fall investor day47:37 "Addback city": cleaning up the earnings number50:02 The European discount: real or imagined?Links:Yet Another Value Blog - https://www.yetanothervalueblog.comSee our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimerProduction and editing by The Podcast Consultant - https://thepodcastconsultant.com/

Abivax posted maybe the best ulcerative colitis data anyone's seen, then crashed 60% on a cancer signal Adam May argues is statistical noise. We dig into whether $ABVX is now a mispriced takeout: the maintenance efficacy that beat Rinvoq, how the scary "seven cancer cases" collapse to two, the blackbox question, the Crohn's skew, and the part two safety data due within weeks. Then a quick look at Nectar (NKTR), its alopecia areata data, and the Eli Lilly lawsuit.This episode is sponsored by AlphaSense, and specifically Andrew's upcoming AI webinar with them: breaking down the modern AI stack for investors with Dave Wang (Wall Street Prompts) and Ben Collins (AlphaSense). Goes live June 25. Register here. Chapters:00:00 Intro and disclosure (long ABVX and NKTR)01:03 Sponsor: AlphaSense AI webinar for investors02:33 The biotech "GOAT" returns03:33 Abivax setup: induction vs maintenance, the stakes06:38 The bar: clinical remission and Rinvoq10:14 Blowout maintenance data, and endoscopic remission that doubles Rinvoq14:23 The data drops, then a 60% crash16:31 The cancer scare, taken apart case by case24:45 Why it's statistical noise: mechanism, clustering, base rates28:50 Adverse-event capture and the phase 2 safety database33:57 Bear case: hasn't the market had time to digest this?38:00 Blackbox or no blackbox, and does it matter at $10040:32 The Crohn's readout and the skew45:36 M&A: timing, the new CCO, what Adam wants them to do47:38 Part two safety data due within weeks54:46 The cash question: secondary vs sale57:49 Nectar: strong data, then an unexplained selloff59:54 The Eli Lilly lawsuit and the jury-trial angle01:03:26 Ox40 read-through and the Q32 Bio overhang01:06:07 Most mispriced pick, targets, and the CEO's Cincor parallel01:12:10 WrapLinks:Yet Another Value Blog - https://www.yetanothervalueblog.comSee our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimerProduction and editing by The Podcast Consultant - https://thepodcastconsultant.com/Disclosure: Long ABVX and NKTR

Amadeus $AMS is down roughly 25% because the market lumped it in with the SaaS names AI is supposed to gut. Team Amadeus, Pershing Square Challenge finalists, argue it's the opposite: a deterministic, mission-critical monopoly that AI makes more valuable, not less. We dig into the 50-year-old systems that planes literally can't take off without, why the GDS is the wrong job for an LLM, the Sabre and Constellation Software angle, and what the stock is actually worth.Full pitch deck (~75 pages): https://www.dropbox.com/scl/fi/5bwef8mz2kplx2sub598w/PSC_AMS_LONG_vSent.pdf?rlkey=x5g0v7t1qk8hpg00ewix95hn3&st=rq9nzl4h&dl=0This episode is brought to you by Trata. Trata is two investors who get on an anonymized call and talk through the real issues in a stock, bull-to-bull, bear-to-bear, or just getting up to speed. If you like this podcast, you'll like Trata. Check it out at trata.comChapters:00:00 Why Amadeus landed on my radar01:00 Sponsor: Trata02:39 Meet Team Amadeus (Pershing Square Challenge finalists)05:20 What Amadeus actually does: the toll booth on global travel09:07 The AI fear that broke the stock11:13 Is it actually cheap? Valuation and stock comp15:26 Why Amadeus tops the AI-risk matrix16:32 Air IT Solutions: the SAP of airlines22:59 The Microsoft AI director who bet against AI eating this24:15 Tech-debt pushback and the JFK field trip29:09 Sabre, Constellation Software, and the monopoly complaint33:16 How Amadeus won share during COVID34:21 The air-distribution network effect35:22 Why LLMs are the wrong tool for the GDS39:50 The $1B biometrics acquisition43:03 Google, Gemini, and the uptime math45:47 Fair value and the bull case nobody's pricing49:01 Amadeus as an AI beneficiary51:02 Closing thoughtsLinks:Yet Another Value Blog - https://www.yetanothervalueblog.comSee our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimerProduction and editing by The Podcast Consultant - https://thepodcastconsultant.com/

A market that refuses to go down, AI coming for the investor's job, and MicroStrategy quietly becoming the entire preferred-equity market. Andrew's monthly ramble across five things he can't stop thinking about: stretched memory valuations, a hyper-concentrated tape, mental flexibility, and the cycle nobody believes can break.This episode is sponsored by Fiscal.ai. Modern financial data for global equities, with a self-serve API that plugs fundamentals and prices straight into your LLM and updates within minutes of earnings, not days. Get 15% off at https://fiscal.ai/yavChapters:00:00 Five things I'm rambling on this month01:58 Sponsor: Fiscal.ai03:16 "We'll never have problems again": a market that won't quit04:56 Energy and oil: the worries the market keeps shrugging off06:00 AI, space plays, and stretched memory valuations09:54 Five stocks, half the S&P's gains10:51 Is AI coming for the investor's job?13:08 The counterpoint: 200-IQ machines and more fragile markets16:10 Mental flexibility: why your old letters predicted your AI take20:04 Why "the cycle is dead" always worries me21:42 MicroStrategy is the preferred-equity market now24:45 The CFO signal: leaving a big company for a small oneLinks:Yet Another Value Blog - https://www.yetanothervalueblog.comSee our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimerProduction and editing by The Podcast Consultant - https://thepodcastconsultant.com/